WO2021167308A3 - 항암제 프로드러그 컨쥬게이트의 새로운 용도 - Google Patents

항암제 프로드러그 컨쥬게이트의 새로운 용도 Download PDF

Info

Publication number
WO2021167308A3
WO2021167308A3 PCT/KR2021/001925 KR2021001925W WO2021167308A3 WO 2021167308 A3 WO2021167308 A3 WO 2021167308A3 KR 2021001925 W KR2021001925 W KR 2021001925W WO 2021167308 A3 WO2021167308 A3 WO 2021167308A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug conjugate
anticancer agent
novel use
genotype
agent prodrug
Prior art date
Application number
PCT/KR2021/001925
Other languages
English (en)
French (fr)
Other versions
WO2021167308A2 (ko
Inventor
김상환
김상윤
변영로
조한희
Original Assignee
울산대학교 산학협력단
파로스젠 주식회사
재단법인 아산사회복지재단
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울산대학교 산학협력단, 파로스젠 주식회사, 재단법인 아산사회복지재단, 서울대학교산학협력단 filed Critical 울산대학교 산학협력단
Publication of WO2021167308A2 publication Critical patent/WO2021167308A2/ko
Publication of WO2021167308A3 publication Critical patent/WO2021167308A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 난치성 암으로 알려진 KRAS 변이체 유전자형 또는 PTEN 단백질 소실 유전자형을 갖는 암에 대한 효과적인 치료를 위해, 알부민 결합 기능기(albumin binding moiety), 링커 및 항암 화학요법제를 포함하는 항함 화학요법제 프로드러그 컨쥬게이트를 포함하는 KRAS 변이체 또는 PTEN 단백질 소실 유전자형을 갖는 암 치료용 약학적 조성물을 제공한다.
PCT/KR2021/001925 2020-02-17 2021-02-15 항암제 프로드러그 컨쥬게이트의 새로운 용도 WO2021167308A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0019242 2020-02-17
KR1020200019242A KR102436012B1 (ko) 2020-02-17 2020-02-17 항암제 프로드러그 컨쥬게이트의 새로운 용도

Publications (2)

Publication Number Publication Date
WO2021167308A2 WO2021167308A2 (ko) 2021-08-26
WO2021167308A3 true WO2021167308A3 (ko) 2021-10-14

Family

ID=77391020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/001925 WO2021167308A2 (ko) 2020-02-17 2021-02-15 항암제 프로드러그 컨쥬게이트의 새로운 용도

Country Status (2)

Country Link
KR (1) KR102436012B1 (ko)
WO (1) WO2021167308A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230085578A (ko) * 2021-12-07 2023-06-14 한국과학기술연구원 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150023912A1 (en) * 2012-02-21 2015-01-22 Ktb Tumorforschungsgesellschaft Mbh Combinations of albumin-based drug delivery systems
KR20160060537A (ko) * 2014-11-20 2016-05-30 파로스젠 주식회사 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150023912A1 (en) * 2012-02-21 2015-01-22 Ktb Tumorforschungsgesellschaft Mbh Combinations of albumin-based drug delivery systems
KR20160060537A (ko) * 2014-11-20 2016-05-30 파로스젠 주식회사 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEQUET-ROMERO M., DÍAZ Y.M., RAMÍREZ J.S., SELMAN-HOUSEIN K.-H., HERNÁNDEZ-BERNAL F., DE LA TORRE SANTOS A., PIÑERO J., BERMÚDEZ C: "Active immunotherapy with a VEGF targeted vaccine HeberSaVax: The road so far and the future ahead", ANNALS OF ONCOLOGY, KLUWER DORDRECHT, NL, vol. 29, 1 March 2018 (2018-03-01), NL , pages iii10, XP055855871, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy047 *
JUNG, SEONG U.: "Design and development of multi-targeted anticancer agents for anti-angiogenic therapy or tumor tissue-selective delivery", PH.D. THESIS, DEPT. OF PHARMACY, GRADUATE SCHOOL OF SEOUL NATIONAL UNIVERSITY, February 2015 (2015-02-01), pages 1 - 248, XP009530960 *
PADAVANO JULIANNA, HENKHAUS REBECCA S., CHEN HWUDAURW, SKOVAN BETHANY A., CUI HAIYAN, IGNATENKO NATALIA A.: "Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer through GTPase Signaling Pathways", CANCER GROWTH AND METASTASIS 2017, vol. 8s1, 1 January 2015 (2015-01-01), pages CGM.S29407 - 1, XP055855870, ISSN: 1179-0644, DOI: 10.4137/CGM.S29407 *

Also Published As

Publication number Publication date
KR20210104463A (ko) 2021-08-25
WO2021167308A2 (ko) 2021-08-26
KR102436012B1 (ko) 2022-08-24

Similar Documents

Publication Publication Date Title
Shefet-Carasso et al. Antibody-targeted drugs and drug resistance—challenges and solutions
Nasiri et al. Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy
WO2022060836A8 (en) Indole derivatives as ras inhibitors in the treatment of cancer
Sharma et al. Recent advances in microbial toxin-related strategies to combat cancer
WO2020126609A3 (en) Antibody drug conjugates (adc) containing saponin
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
AU2022345316A1 (en) Anti-her3 antibody drug conjugate, composition thereof, and use thereof
MX2020012130A (es) Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2.
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2021167308A3 (ko) 항암제 프로드러그 컨쥬게이트의 새로운 용도
WO2020225805A3 (en) Precursor tri-specific antibody constructs and methods of use thereof
MX2021011653A (es) Composiciones inmunoterapeuticas y uso de las mismas.
WO2022235870A8 (en) Ras inhibitors for the treatment of cancer
AU2021289730A8 (en) BRM targeting compounds and associated methods of use
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
MX2023001648A (es) Conjugado de anticuerpo y farmaco.
MX2023001788A (es) Composiciones y metodos de enlazadores escindibles.
Kim et al. Preclinical evaluation of antisense bcl‐2 as a chemosensitizer for patients with gastric carcinoma
MX2023005301A (es) Compuestos dirigidos a brm y metodos de uso asociados.
WO2003044161A3 (en) Gene amplification and overexpression in cancer
WO2020232191A8 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
EP0745390A3 (en) Polymeric prodrugs for beta-lactamase and uses thereof
WO2022122765A3 (en) Antibody and taxane combination therapy
WO2021202830A3 (en) Hsp90-binding conjugates and formulations thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21757873

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21757873

Country of ref document: EP

Kind code of ref document: A2